Diabetes Digest is 10 years old and still thriving. Our original aim remains valid: to keep healthcare professionals up-to-date with new research that may impact their clinical practice. We have been particularly fortunate in being able to retain an excellent Editorial Board who produce the reviews and comments on the highlighted articles. We thank them.
Of course, we thank our readership – apparently Diabetes Digest is read in all sorts of places including trains, planes and bathrooms! We feel proud that Diabetes Digest is one of the few journals from which every member of the team – whether in primary or secondary care – can take something valuable from; be it an overview of all that is happening in diabetes research, or access to the findings of specific articles published in journals outside those usually read by the healthcare professional providing diabetes care. Importantly, Diabetes Digest continues to not simply communicate recent research findings, but rather to comment on what the research means at the clinical coalface – the implications, not just the facts.
The biggest change that we have seen since our lanuch in 2001 has been the huge impact of the Internet. We are forever discussing the pros and cons of online publishing, the need for an electronic version of the journal. However, one thing we will not change is our original idea of including a “WOW! factor” for each article – this seems to produce more debate than any other aspect of the journal.
Both the Publisher and Editor-in-Chief of Diabetes Digest are 10 years longer in the tooth. Although we are increasingly preoccupied by pension schemes, bus passes and winter fuel allowances, we believe that the journal will be around as long as high-quality research is being undertaken. The challenge for all of us is to make sure that the UK remains at the forefront of producing the material that helps clinicians to continue to deliver care of the highest quality for people with diabetes. We look forward to the next 10 years!
Amid accumulating evidence of benefits with new diabetes drugs, Vinod Patel asks whether the costs can be justified.
9 Nov 2023